Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.96
(30.67%)
USD 1.96
(30.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | 77.5 Million USD | 7630.58% |
| 2021 | 2.76 Million USD | -97.18% |
| 2020 | 30.02 Million USD | 2.34% |
| 2019 | 28.17 Million USD | -41.68% |
| 2018 | 40.44 Million USD | -36.6% |
| 2017 | 77.82 Million USD | 53.5% |
| 2016 | 55.02 Million USD | 1899.42% |
| 2015 | 2.69 Million USD | 113.83% |
| 2014 | -18.75 Million USD | -122.24% |
| 2013 | -8.41 Million USD | 57.01% |
| 2012 | -19.61 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | 10.74 Million USD | -8.52% |
| 2023 Q1 | 11.74 Million USD | -23.14% |
| 2022 Q1 | 58.93 Million USD | 3540.15% |
| 2022 FY | - USD | 7630.58% |
| 2022 Q2 | -3.68 Million USD | -106.25% |
| 2022 Q3 | 1.54 Million USD | 141.99% |
| 2022 Q4 | 15.28 Million USD | 888.62% |
| 2021 FY | - USD | -97.18% |
| 2021 Q3 | -11.36 Million USD | -265.52% |
| 2021 Q4 | 1.61 Million USD | 114.25% |
| 2021 Q2 | 6.86 Million USD | 158.24% |
| 2021 Q1 | 2.65 Million USD | -79.44% |
| 2020 Q3 | 10.78 Million USD | 48.04% |
| 2020 Q1 | -981 Thousand USD | -118.35% |
| 2020 Q2 | 7.28 Million USD | 842.61% |
| 2020 Q4 | 12.93 Million USD | 19.9% |
| 2020 FY | - USD | 2.34% |
| 2019 Q2 | 11 Million USD | -20.25% |
| 2019 Q4 | 5.34 Million USD | 379.36% |
| 2019 Q3 | -1.91 Million USD | -117.4% |
| 2019 FY | - USD | -41.68% |
| 2019 Q1 | 13.79 Million USD | -15.28% |
| 2018 Q3 | 19.33 Million USD | 84.62% |
| 2018 Q2 | 10.47 Million USD | 213.31% |
| 2018 Q1 | 3.34 Million USD | -67.72% |
| 2018 FY | - USD | -36.6% |
| 2018 Q4 | 16.28 Million USD | -15.79% |
| 2017 Q4 | 10.35 Million USD | -61.22% |
| 2017 Q2 | 6.86 Million USD | -79.58% |
| 2017 Q1 | 33.6 Million USD | 18.78% |
| 2017 FY | - USD | 53.5% |
| 2017 Q3 | 26.7 Million USD | 289.12% |
| 2016 Q1 | -2.62 Million USD | -319.57% |
| 2016 Q4 | 28.29 Million USD | 122.79% |
| 2016 Q3 | 12.7 Million USD | -9.27% |
| 2016 Q2 | 13.99 Million USD | 633.05% |
| 2016 FY | - USD | 1899.42% |
| 2015 Q4 | 1.19 Million USD | 111.53% |
| 2015 FY | - USD | 113.83% |
| 2015 Q3 | -10.37 Million USD | -24.7% |
| 2015 Q2 | -8.31 Million USD | -141.38% |
| 2015 Q1 | 20.09 Million USD | 406.78% |
| 2014 Q3 | -9.1 Million USD | -213.08% |
| 2014 FY | - USD | -122.24% |
| 2014 Q4 | -6.55 Million USD | 28.02% |
| 2014 Q2 | -2.9 Million USD | 18.49% |
| 2014 Q1 | -3.56 Million USD | -17.58% |
| 2013 Q2 | 1.24 Million USD | 129.02% |
| 2013 Q1 | -4.3 Million USD | -50.92% |
| 2013 Q3 | -2.5 Million USD | -300.14% |
| 2013 FY | - USD | 57.01% |
| 2013 Q4 | -3.03 Million USD | -21.31% |
| 2012 Q3 | -3.86 Million USD | 0.0% |
| 2012 Q4 | -2.85 Million USD | 26.16% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bright Green Corporation | - USD | -Infinity% |
| BioQuest Corp. | -33.57 USD | 230866945.398% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 561.212% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 2075.905% |
| GSRX Industries Inc. | - USD | -Infinity% |
| High Sierra Technologies, Inc. | -181.97 Thousand USD | 42690.303% |
| Instadose Pharma Corp. | - USD | -Infinity% |